Home > Riviste > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Fascicoli precedenti > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2020 May;179(5) > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2020 May;179(5):317-25

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2020 May;179(5):317-25

DOI: 10.23736/S0393-3660.19.04030-0

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

Access of medicines to the market: three years’ experience of Sicily’s regional drug formulary

Valeria PIZZIMENTI 1, Dario FORMICA 1, Janet SULTANA 2, Simona LUCCHESI 3, Andrea AIELLO 4, Valentina IENTILE 1, Gianluca TRIFIRÒ 1, 2, 5

1 Unit of Clinical Pharmacology, G. Martino University Hospital, Messina, Italy; 2 Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy; 3 Department of Chemical Sciences, Biological, Pharmaceutical and Environmental, University of Messina, Messina, Italy; 4 Department of Pricing and Market Access, Creativ-Ceutical, Milan, Italy; 5 Department of Medical Informatics, Erasmus Medical Center, Zuid-Holland, Rotterdam, the Netherlands



BACKGROUND: In Italy, pharmaceutical market access depends on European Medicines Agency (EMA), Italian national drug agency (AIFA) and regional regulatory procedures (Sicilian Drug Formulary Committee). The regulatory and economic outcomes of the Sicilian Regional Drug Formulary Committee have not yet been described. The objective of this study was to quantify: 1) the number of drugs approved regionally; 2) the drug review time by European, national and regional competent authorities; 3) regional healthcare expenditure associated with the approved drugs.
METHODS: All drugs approved by the Sicilian Drug Formulary Committee between 1st January 2013 to 1st April 2016 were identified. For these drugs, the median (with interquartile range, IQR) approval time taken by the European, national and regional competent authorities were estimated for all drugs and innovative drugs separately. Finally, the economic impact of regional regulatory decisions was estimated one year after drug approval.
RESULTS: In total 117 drugs were approved. Median (IQR) time between EMA and AIFA approval was 1.17 years (0.93-1.66), while between AIFA and the Sicilian regional approval this was 0.35 years (0.27-0.94). The time elapsed for innovative drugs was 0.91 years (IQR: 0.66-1.75) between EMA and AIFA and 0.13 years (IQR: 0.02-0.25) between AIFA and Sicilian regional approval. Regional drug approvals were associated with a yearly cost of € 525,489,586.
CONCLUSIONS: The approval of 117 drugs over 3 years was associated with a € 525 million pharmaceutical expenditure yearly. The total median time for pharmaceutical market access in Sicily was 1.52 years, and 1.04 years for innovative drugs.


KEY WORDS: Pharmaceutical preparations; Health care costs; Drug approval; Health services

inizio pagina